Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	POKRIVČÁK Tomáš NAVRÁTIL Jiří POPRACH Alexandr STANÍK Michal KISS Igor
Year of publication	2024
Type	Article in Periodical
Magazine / Source	CASE REPORTS IN ONCOLOGY
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://karger.com/cro/article/17/1/537/898017/Long-Term-Efficacy-and-Safety-of-Enzalutamide
Doi	http://dx.doi.org/10.1159/000538124
Keywords	Enzalutamide; Metastatic castration-resistant prostate cancer; Aged 75 and over; Comorbidity
Description	Introduction: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. Case Presentation: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. Conclusion: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.